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Available online 16 January 2016The ﬂavonoid astilbin is themajor active component extracted from the rhizomeof Smilax glabra, which has been
widely used in China to treat inﬂammatory and autoimmune diseases, Psoriasis is a common chronic inﬂamma-
tory disease in which T helper 17 (Th17) cells play an important role, provoking inﬂammation.We employed an
imiquimod (IMQ)-induced psoriasis-like mouse model to investigate the effect of astilbin in inﬂammation. Mice
were administered 25 to 50mg/kg astilbin. Inﬂammation of psoriasis-like lesions was assessed by histology, cir-
culating levels of T cellswere assessed byﬂow cytometry and cytokines by bead-based immunoassay. Jak/Stat3 in
isolated T cells was assessed byWestern blotting and RORγt expression was assessed by RT-PCR. Administration
of astilbin ameliorated IMQ-induced keratinocyte proliferation, inﬁltration of CD3+ cells to psoriatic lesions and
ameliorated elevations in circulating CD4+ and CD8+ T cells and inﬂammatory cytokines (IL-17A, TNF-α, IL-6,
IFN-γ and IL-2). In vitro, astilbin inhibited Th17 cell differentiation and IL-17 secretion of isolated T cells, and
inhibited Jak/Stat3 signaling in Th17 cells, while up-regulating Stat3 inhibitor SCOSE3 expression in psoriatic le-
sions. Thus, astilbin likely alleviates psoriasis-like skin lesions by inhibiting Th17 related inﬂammation. Astilbin
represents as an interesting candidate drug for immunoregulation of psoriasis.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inﬂammation1. Introduction
Psoriasis is a chronic immune-mediated inﬂammatory erythemato-
squamous dermatosis disorder, characterized by uncontrolled
keratinocyte proliferation, recruitment of T cells to the skin and release
of pro-inﬂammatory cytokines [1]. Although themolecularmechanisms
governing psoriasis pathogenesis are unclear, many studies have indi-
cated that T helper 17 (Th17) cells play an important role in the devel-
opment of psoriasis lesions [2]. Th17 cells are reported to inﬁltrate
psoriasis lesions, and levels of circulating Th17 cells in the peripheral
blood are elevated in psoriatic patients, and positively correlate with
the Psoriasis Area and Severity Index (PASI) [3]. Naïve CD4+differenti-
ate into Th17 cells in the presence of Transforming growth factor (TGF)-
β, interleukin (IL)-6, and IL-1β, and their survival and activation are
modulated mainly by IL-23. Th17 cells are the main source of IL-17nal Chinese Medicine, afﬁliated
ional Chinese Medicine, Beijing
ditional Chinese Medicine on
. This is an open access article underfamily cytokines, and IL-17 has been recognized as a key cytokine in es-
tablishment and maintenance of the psoriatic phenotype [4]. IL-17A
binds receptors expressed on keratinocytes, dendritic cells, dermal ﬁ-
broblasts and endothelial cells [5]. Three inhibitors targeting IL-17A or
its receptor (secukinumab, ixekizumab and brodalumab) have demon-
strated encouraging results in phase II clinical trials and have been suc-
cessfully applied in treatment of psoriasis, psoriatic arthritis and
spondyloarthritis [6].
The ﬂavonoid astilbin is a major active component of the rhizome of
Smilax glabra and other herbs which have been traditionally used to
treat psoriasis. Astilbin has been reported to possess multiple clinically
relevant bioactivities, including antioxidant [7], anti-inﬂammatory [8],
anti-arthritic [9], and anti-diabetic nephropathy properties [10]. Never-
theless, the molecular mechanisms by which astilbin interacts with in-
ﬂammatory processes are poorly understood.
Previous studies reported that astilbin down-regulates T cell activity
by selectively inducing apoptosis, stimulating negative regulatory cyto-
kine (IL-10) [11] and suppressing activated T cell adhesion and migra-
tion [11] in inﬂammatory disease, such as collagen-induced arthritis
[12] and hypersensitivity [13]. In addition, astilbin not only inhibited T
lymphocyte function in acute heart allograft rejection, but also inhibited
migration and antigen presenting of dendritic cells (DCs) [14], andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primers used in RT-qPCR.
Primers Sequences (5′ to 3′) Product (bp)
RORr pf AACTGGCTTTCCATCATCATCTCTG 157
RORr pr GGGAAGGCGGCTTGGACCACGAT
Actin pf GCCTTCCTTCTTGGGTAT 97
Actin pr GGCATAGAGGTCTTTACGG
33T.-T. Di et al. / International Immunopharmacology 32 (2016) 32–38astilbin was recently reported to reduce activation of both T and B cells
in lupus-pronemice [15]. These activities are associated with inhibition
of nuclear factor κB (NF-κB) and p38 phosphorylation. However, in a
mousemodel of dextran sulfate sodium (DSS)-induced acute colitis, ad-
ministration of astilbin increased the number of DCs detected and in-
creased TGF and IL-10 secretion [16]. Furthermore, DCs pretreated
with astilbin enhanced T-regulatory cell (Treg) differentiation.
Astilbin appears to target multiple immune processes, but can be
summarized by inhibition of T cell induced inﬂammation. Astilbin may
thus pose useful clinically in a variety of inﬂammatory diseases with
less associated toxicities and adverse effects than conventional ap-
proaches [17,18].
In this paper, we sought to investigate the effect of isolated astilbin
on a mouse model of psoriasis. We found that astilbin signiﬁcantly
inhibited inﬂammatory responses and keratinocyte over-proliferation
in a mouse model of imiquimod (IMQ)-induced psoriasis. In vitro,
astilbin reduced Th17 cell differentiation and suppressed and IL-17 se-
cretion in a dose dependent manner. Our ﬁndings suggest astilbin
may improve symptoms of psoriasis by inhibiting Th17 dominated
inﬂammation.Fig. 1.Astilbin treatment ameliorated IMQ-induced skin lesion. Amousemodel of psoriasis was
observed after 7 days in IMQ-treated animals, but not control animals (CON), and animals also ad
ameliorated symptoms. Bar = 50 μm (A). Means ± SDs of total score (B), scaling (D), skin thic
corresponding histological analyses (HE staining) of mouse back skin and epidermal thickne
involucrin (red) (H). Blue = DAPI, bar = 50 μm. *p b 0.05 vs model mice.2. Materials and methods
2.1. A mouse model of psoriasis
BALB/c mice (male, 18 to 20 g, 8 week-old) were purchased from
Beijing HFK Bioscience (China) (certiﬁcation NO. SCXK Jing 2014-
0004), and housed under speciﬁc pathogen-free conditions, with free
access to food andwater. All animal experiments were performed in ac-
cordance with the National Institutes of Health Guidelines on Laborato-
ry Research and approved by the Animal Care Committee of Capital
Medical University.
The mice were separated into the following ﬁve groups of eight
mice. Four groups were administered a daily topical dose of 62.5 mg
of a cream preparation containing 5% IMQ (Mingxinlidi Laboratory,
China) on hair-free back of mice to establish a model of IMQ-induced
psoriasis [19]. The control group (CON) did not receive IMQ. Astilbin
(National Institutes for Food and Drug Control, China), was dissolved
in DMSO, then diluted in normal saline (NS) to achieve a ﬁnal DMSO
concentration b0.1% for oral administration. Themodel group (IMQ) re-
ceived no astilbin; the methotrexate (MTX) group received 1 mg/kg
MTX, a drug used for psoriasis treatment [20]. The astilbin-high group
(AH) received 50 mg/kg astilbin, and the astilbin-low group (AL) re-
ceived 25 mg/kg astilbin. All treatments were operated from the day
IMQ was administrated, once a day for 7 days. The severity was moni-
tored and graded using a modiﬁed human scoring system Psoriasis
Area Severity Index (PASI) [21]. The cumulative score denotes severity
of inﬂammation. After seven daysmicewere sacriﬁced by cervical dislo-
cation under sodium pentobarbital anesthesia, and skin lesions and
serum samples were collected.induced inmice by topical application of imiquimod (IMQ). Psoriasis-like skin lesionswere
ministered 25 or 50mg/kg astilbin (AL andAH) or 1mg/kgmethotrexate (MTX) exhibited
kness (C) and redness scores (E) (n = 4 per experiment). Phenotypical presentation and
ss (F). Mouse back skin IHC staining for proliferating cell nuclear antigen (red) (G) and
34 T.-T. Di et al. / International Immunopharmacology 32 (2016) 32–382.2. Isolation of naïve CD4+ T cells and in vitro induction of Th17
differentiation
Total splenic T cells were puriﬁed by negative selection with the
Mouse naïve CD4+ T Cell Isolation Kit and “The Big Easy” Magnet
(EasySep, USA) following the manufacturer's instructions, then further
puriﬁed to N95%. CD4+ purity by FACS-sorting (BD FACSVerse™,
Germany) with anti-CD4 FITC (Miltenyi Biotec, Germany). For gating,
viable cells were selected based on their FSC values; then, T-helperFig. 2. Astilbin inhibited T cell-mediated inﬂammatory inﬁltration. CD3-positive cells in IMQ-in
based immunoassay of key psoriasis-related inﬂammatory cytokines demonstrates signiﬁcan
induced mice treated with astilbin (C). *p b 0.05 and **p b 0.01 vs model mice. Scale bar = 50cells were isolated as CD4+ cells, which represented N97% total viable
cells.
T cells were seeded in 12 well plates containing plate bound anti-
CD3 (5 μg/ml, BD Pharmingen, USA) and soluble anti-CD28 (2 μg/ml,
BD Pharmingen, USA) antibodies at 2 × 106 cells/well in RPMI 1640me-
dium (Hyclone, Carlsbad, CA) containing 15% inactivated fetal bovine
serum (Hyclone, Carlsbad, CA).
For Th17 cell differentiation, splenic T cells were cultured with
5 ng/ml TGF-β, 20 ng/ml IL-6, 10 ng/ml IL-1β, and 15 ng/ml IL-23duced mice (A). CD4+ and CD8+ T cells in inguinal lymph nodes and spleen (B). Bead-
t decreases in IL-17A, IL-6, TNF-α, IFN-γ, IL-2, IL-4 and IL-10 in peripheral blood of IMQ-
μm.
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rected antibodies (R&D Systems, USA) as indicated [22]. Th17 differen-
tiation was assessed by ﬂow cytometry, as previously described [14].
Astilbin (N98%,molecularweight of 450.40, Chinese institute of food
and drug identiﬁcation) was dissolved in dimethyl sulfoxide (DMSO),
and cells were incubated with the indicated concentrations for three
days. In control groups, DMSO was used at amounts similar to those of
treatment groups.
2.3. Cell viability assays
Cell viabilitywas assessedusing theCell CountingKit-8 (CCK8) assay
(Dojindo Laboratory, Japan) according to the manufacturer's instruc-
tions at 3 days after induction of Th17 differentiation. The mean optical
density (OD) of the three wells in each group was used to calculate the
percentage of cell proliferation.
2.4. Flow cytometry analysis
Cells were stained with anti-CD3-APC, anti-CD8-PE and anti-CD4-
FITC antibodies (BD Pharmingen, USA). Prior to IL-17A staining, cells
were incubated with Leukocyte Activation Cocktail and BD GolgiPlug
for 6 h, then suspended in ﬁxation/permeabilization solution (BD
Cytoﬁx/Cytoperm kit-BD Pharmingen, USA), and stained with anti-IL-
17A-PE antibody (BD Pharmingen, USA). The concentration of cytokines
in peripheral blood was assessed using the Th1/Th2/Th17 CBA Kit (BD
Pharmingen, USA) according to the manufacturer's instructions.
2.5. Immunochemical staining and immunoﬂuorescence staining
Skin samples from the back lesions ofmicewere collected in 10% for-
malin and embedded in parafﬁn. Sections (5 μm)were stained with he-
matoxylin and eosin (HE) and anti-Rabbit CD3, proliferating cell nuclear
antigen (PCNA), involucrin and IL-17 antibodies (Abcam, USA) diluted
1:500, and staining was assessed using light and ﬂuorescence micro-
scopes (Olympus, Japan).
2.6. Western blotting
Skin samples were lysed and the protein was resolved in 10% SDS-
PAGE. The membrane fraction was incubated with mouse-anti-total or
phosphorylated Stat3, jak2 and jak3 antibodies, rabbit-anti-SCOSE3 an-
tibody (Cell Signal Technology, Danvers, MA) and rabbit-anti-β-actin
antibody (Santa Cruz, CA), then IRDye 700DX- or 800DX-conjugated
secondary antibodies (Rockland Inc., Gilbertsville, PA). Immunoﬂuores-
cence was assessed by Odyssey infrared imaging system (LICOR Biosci-
ences, Lincoln, NB).
2.7. Real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted from skin lesions using TRIzol (Invitrogen,
USA) and puriﬁed using a NucleoSpin RNA Clean-up Kit (Macherey-
Nagel, Germany). Complementary DNA was generated using an
AfﬁnityScript Multiple Temperature cDNA Synthesis Kit (Agilent Tech-
nologies, USA) and speciﬁc primers (Table 1), and the relative expres-
sion levels of genes were determined with an ABI 7500 Fast Real-Time
PCR System using real-time PCR master mix (Roche, USA). The actin
gene was used as a reference to normalize the data.
2.8. Statistical analyses
All data were expressed as mean± standard deviation (SD) or orig-
inal data representing one of at least three independent experiments.
One-way analysis of variance (ANOVA) followed by Newman–Keul's
post hoc test was used to compare multiple groups. Unpaired Studentt-test was performed to compare two groups. p b 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Astilbin ameliorated abnormal proliferation and differentiation of
keratinocytes in a mouse model of psoriasis
To investigate whether astilbin has a beneﬁcial effect on psoriasis,
we administered astilbin to a mouse model of psoriasis. Psoriasis was
induced in mice by topical application of IMQ. After seven days, typical
erythema, scaling and thickening were observed in IMQ-induced skin
lesions. The weight of mice orally administered 25 or 50 mg/kg astilbin
did not differ signiﬁcantly from control animals, and astilbin-treated an-
imals had smoother skin, more shallow erythema and sparser scales
(Fig. 1A–E).
IMQ-treated skin lesions exhibited increased epidermal hyperplasia,
elongated ‘rete-like’ ridges, acanthosis in the epidermis and
perivascular inﬁltration of the inﬂammatory cells in the upper dermis,
a phenotype typical of humanpsoriatic skin, but astilbin signiﬁcantly re-
duced the thickness of the epidermis layer, and attenuated IMQ-
induced psoriasis (Fig. 1F).
PCNA is expressed in proliferative cells, especially the basal cell. Ex-
pression of PCNA was reduced in the skin lesions of astilbin-treated
mice, suggesting that astilbin reduces IMQ-induced proliferation of
keratinocytes (Fig. 1G). Expression of involucrin in keratinized epider-
mis cells was observed throughout the epidermal layer of lesions, but
involucrin expression was decreased in astilbin-treated mice and limit-
ed to the top layer (Fig. 1H). These results suggest that the administra-
tion of astilbin effectively ameliorates IMQ-induced keratinocyte
differentiation.
3.2. Astilbin inhibited T cell-mediated inﬂammatory inﬁltration in a mouse
model of psoriasis
We then investigated the impact of astilbin on inﬂammatory inﬁltra-
tion. Inﬁltration of CD3+ cells was observed in IMQ-induced lesions,
but reduced in astilbin-treated mice (Fig. 2A). The inguinal lymph
nodes and spleen in IMQ-treated mice were enlarged, and absolute
numbers of CD4+ and CD8+ T cells were elevated in inguinal lymph
nodes and the spleen. The weight of lymph nodes and spleen were re-
duced in astilbin-treated mice, and the dysregulation of CD4/CD8 cell
in both tissues was ameliorated (Fig. 2B).
IMQ up-regulated the levels of psoriasis related cytokines in the pe-
ripheral blood of mice, indicating systemic immunity activation. The
level of circulating IL-17A was increased by over 25 fold, IL-10 by 15
fold, IL-4 by 9 fold, IL-2 by 8 fold, IL-6 and IFN-γ by 6 fold, and TNF-α
by 3 fold. In astilbin-treated mice levels of IL-17A, IL-6, TNF-α, IFN-γ,
IL-2 and IL-4 in peripheral blood were signiﬁcantly decreased
(p b 0.05). Interestingly, IL-10 levels were also reduced in astilbin-
treated mice (Fig. 2C).
3.3. Astilbin inhibited Th17 cell differentiation in vitro and IL-17A secretion
in a mouse model of psoriasis
To investigate how astilbin inﬂuences Th17 cell function, we ﬁrst in-
vestigated whether astilbin affected the viability of isolated, Th17 cells
in vitro using the CCK8 assay. While 0.1–10 μg/ml astilbin did not affect
Th17 cell viability, at concentrations over 100 μg/ml Th17 viability de-
clined, thus in subsequent experiments we use the dose range of 0.1–
10 μg/ml (Fig. 3A).
To investigate the effect of astilbin on Th17 cell differentiation, we
measured the fraction of IL-17A+ cells and IL-17A secretion before
and after incubation with astilbin by ﬂow cytometry and bead-based
immunoassay, respectively. Astilbin reduced Th17 cell differentiation,
and IL-17A secretion in a dose-dependent manner (Fig. 3B and C).
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Fig. 4.Astilbin inhibited activation of Stat3 signaling pathway. The levels of Stat3 and phosphorylated Stat3, Jak3 andphosphorylated Jak3 reduced in astilbin treatedmicewere assessed by
Western blotting. The expression of SCOSE3was increased in the treatment groupmice comparedwith themodelmice. A, Immunoblot showing the bands detected for various proteins. B,
quantitation of A, after normalization with β-actin. *p b 0.05 and **p b 0.01 vs IMQ group.
37T.-T. Di et al. / International Immunopharmacology 32 (2016) 32–38In model mice, IL-17A was mainly observed in the epidermal
keratinocytes and dermal layer, but in astilbin-treated mice inﬁltration
of IL-17A+ cells into skin lesions was reduced (Fig. 3D) and expression
of Th17 speciﬁc transcription factor RORγtmRNAwas reduced (Fig. 3E).
These results suggest that astilbin could directly inhibit the differentia-
tion and function of Th17 cells.
3.4. Stat3 signaling mediated the inhibitory effects of astilbin in a mouse
model of psoriasis
Stat3 has emerged as an important regulator of keratinocytes and
Th17 cell differentiation [17,18]. To investigate whether astilbin in-
ﬂuences Th17 cells by inhibiting Stat3 signaling in psoriasis, in
IMQ-induced skin lesions, we observed increased phosphorylation
of Stat3 and jak3 by Western blotting. The levels of both the phos-
phorylated and non-phosphorylated forms of these proteins de-
creased in high dose astilbin treated mice. Interestingly, expression
of SCOSE3 was increased in astilbin-treated mice (Fig. 4). These re-
sults suggest that astilbin might inhibit Th17 cells activity by a mo-
lecular mechanism involving inhibition or interruption of the Stat3
signaling pathway.
4. Discussion
In this study we investigated the effect of astilbin in a mouse
model of psoriasis. We established IMQ-induced psoriasis-like skin
lesions in BALB/c mice, and found that astilbin signiﬁcantly amelio-
rated keratinocyte proliferation and inﬂammatory inﬁltration and
the gross, histological, cellular and molecular changes. Astilbin re-
duced inﬁltration of CD3+ cells to psoriatic lesions and ameliorated
elevations in circulating CD4 and CD8+ T cells and inﬂammatory cy-
tokines. Astilbin at 50mg/kg generally conferred slightly higher ben-
eﬁts compared with the low dose of 25 mg/kg. Based on these data,
50 mg/kg astilbin would be more suitable for psoriasis. This dose is
similar to that previously used in a DSS induced colitis model [16].
However, the optimal dose should be determined in further studies.
In vitro, astilbin inhibited Th17 cell differentiation, IL-17 secretion,
and Jak/Stat3 signaling in Th17 cells, and up-regulated SCOSE3 ex-
pression in psoriatic lesions. Thus, astilbin represents and interesting
candidate drug to antagonize local inﬂammation in psoriasis by in-
tervening in Th17 cell function.Fig. 3.Astilbin inhibited Th17 cell differentiation and function. Viability of astilbin-treatedCD4+
was analyzed with by cytometry (B). The concentration of IL-17A in supernatants measured by
IMQ-inducedmice (D). RORγt mRNA expression in IMQ-induced skin lesions (E). Flow cytomet
DMSO control groups were represented by the 0 group (A) or Th17 polarizing group (B and C)
Th17 cells or IMQ-induced mice. Red = IL-17A, Blue = DAPI. Scale bar = 50 μm.Previous studies reported that astilbin down-regulates T cell activity
[15], inducing apoptosis, stimulating negative regulatory cytokine ex-
pression, suppressing activated T cell adhesion and migration [11]. In
agreement, we found that astilbin reduced the numbers of T cells in
skin lesions, and decreased CD4+ and CD8+ T cell numbers in inguinal
lymph nodes and spleen specimens. The changes in CD8+ T cells were
less obvious, when relative amounts of cells (%) were assessed. Indeed,
lymph nodes are composed predominantly of T lymphocytes, while the
spleen also contains large numbers of B cells, DCs, and macrophages, so
any changes in T cell composition are less easily detected.
Repeated topical application of IMQ, a Toll-like receptor 7/8 ligand
and potent immune activator, induces and exacerbates inﬂammatory
skin lesions, and has been widely used to model psoriasis skin inﬂam-
mation [21]. This model recapitulates hallmarks of human psoriasis, in-
cluding erythema, hyperkeratosis, scaling, neutrophil micro-abscesses
in the epidermis and T cell inﬁltration in the dermis. Although Th1 T
cells are the predominant cell type in psoriasis, Th17 cells are also impli-
cated in the pathogenesis of plaque psoriasis [23]. A greater proportion
of plasmacytoid dendritic cells (pDCs), DCs and T cells were detected in
the spleen of IMQ-treated mice, and while CD4+ IL-17+ T cells were
also up-regulated, the number of CD4+ IFN-γ+ T cells did not change
signiﬁcantly. As shown above, astilbin attenuated IL-17A expression
both in skin lesions and the peripheral blood. Astilbin directly decreased
the percentage of CD4+ IL-17A+ cells and inhibited IL-17A expression,
suggesting that astilbin not only inhibits Th17 cell differentiation but
also inhibits Th17 cell function, further suppressing Th17-associated in-
ﬂammation. It should be noted that cytotoxic T cells (CD8+) also pro-
duce IL-17 [24]; since CD8+ cell amounts were also altered in spleen
and lymph node specimens from astilbin treated mice, further studies
should assess the speciﬁc impact of astilbin on IL-17 levels in cytotoxic
T cells.
The proinﬂammatory cytokine TNF-α is secreted by Th17 cells and
other inﬂammatory cells, and is considered an important target for
psoriasis treatment [25]. In this model, astilbin reduced TNF-α expres-
sion, and furthermore, reduced expression of Th1 related cytokine
IFN-γ. In addition, astilbin ameliorated IMQ-induced IL-10 expression.
We hypothesize that as increased IL-4 expression protects Th1/Th2 bal-
ance, IL-10 expression accompanies increased proinﬂammatory cyto-
kine secretion, thus acting to suppress inﬂammation and maintain
Th17/Treg balance in this mouse model of psoriasis. As astilbin inhibits
IL-17, IL-10 expression is also reduced. These observationsmay, howev-
er, be model-speciﬁc, as they were not reported by other groups [25].T cellswas assessed byCCK8 assay (A). IL-17A expression of astilibin-treated CD4+T cells
ELISA (C). Representative photographs of immunoﬂuorescence of IL-17A-positive cells in
ric and immunoﬂuorescence results are representative of three independent experiments.
. *p b 0.05 and **p b 0.01 compared with CD4+ T cells without astilbin treating, polarizing
38 T.-T. Di et al. / International Immunopharmacology 32 (2016) 32–38However, our data corroborate previous ﬁndings that astilbin exhibits
overt inhibitory effects on LPS-mediated gene expression of IL-10,
among other inﬂammation mediators [26].
Numerous studies have shown that Stat3 signaling is up-regulated
in both psoriasis and IMQ-induced psoriasis-like lesions [27]. Jak1 and
2 have been implicated in keratinocyte proliferation, activation and ap-
optosis, while Jak3 is predominantly involved in T cell activation and
proliferation [28]. SCOSE3 is a speciﬁc negative regulator of Stat3 pro-
duced by phosphorylation, and RORγt a downstream effector of the
Stat3 pathway involved in Th17 cell activation. We found that astilbin
inhibited phosphorylation of both Stat3 and Jak3, and reduced RORγt
expression, revealing that astilbin may suppress Th17 through the
Jak3/stat3 pathway. In addition, astilbin up-regulated SCOSE3 expres-
sion, suggesting that astilbin directly affectsmultiple processes involved
in Stat3 signaling in IMQ-induced psoriasis-like inﬂammation. Astilbin's
use in targeting IL-17A for psoriasis treatment has many advantages:
Astilbin has relatively low costs; in addition, not only it regulates IL-
17A secretion effectively, astilbin also maintains proper balance of T
cell differentiation. Additional research is required to determine the
precise molecular pathways altered by astilbin, and assess whether
the immune processes underpinning the role of astilbin in IMQ-
induced psoriasis are relevant to psoriasis in humans.
In conclusion, we demonstrated that astilbin alleviates IMQ-induced
psoriasis-like inﬂammation by reducing inﬂammatory cell differentia-
tion and cytokine secretion, in particular directly inhibiting differentia-
tion of Th17 cells and secretion of IL-17A. These ﬁndings indicate new
avenues for the treatment of inﬂammatory diseases of the skin, and sug-
gest that astilbin could serve as a candidate drug for inhibition of local
inﬂammation in psoriasis.
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